Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
|NCT05281471||III||Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab||A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)||CA, FL||View Drugs|| View Results|
|Olvimulogene nanivacirepvec||light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1||Induces immune response and tumor cell lysis||Clinical Trials|
|Bevacizumab||immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin||VEGF antagonist||Approved in Ovarian Cancer|
|Carboplatin||Paraplatin, Novoplatinum||DNA damaging agent||Approved in Ovarian Cancer|
|Cisplatin||CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin||DNA damaging agent||Approved in Ovarian Cancer|
|Gemcitabine||Gemzar||Ribonucleotide reductase and DNA synthesis inhibitor||Approved in Ovarian Cancer|
|Liposomal doxorubicin||Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil||Topoisomerase II inhibitor||Approved in Ovarian Cancer|